Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 9/21/16 → 10/6/23 |
Funding
- Daiichi Sankyo Incorporated: $133,118.00
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 tp 75 Years Old with Newly Diagnosed FLT3-ITD
- Qasrawi, Ayman (PI)
- Hildebrandt, Gerhard (Former PI)